Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100S80C
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥22.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥13.1bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥7.7bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥4.7bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥5.8bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥3.5bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥3.5bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥4.3bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥66.1bnat 2023-09-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥51.3bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥28.6bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥37.5bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥37.5bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥13.6bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥9.2bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥1.8bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.9bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥27.32023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.952023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥27.272023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥32.912023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio56.7%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥63m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥63m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥10.7bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥10.7bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥6.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥11.9bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥11.8bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥63m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥247m
—segment totalrevenue2023-01-01 → 2023-09-30¥22.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥22.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥63m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 601
ItemContextValueUnit
Disposal of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember35630000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember35630000JPY
Disposal of treasury shares ss IFRSCurrentYTDDuration35630000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember936989000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-936989000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-22382000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-22382000JPY
Share based payment transactions ss IFRSCurrentYTDDuration-22382000JPY
Total transactions with owners IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-22382000JPY
Total transactions with owners IFRSCurrentYTDDuration_TreasurySharesIFRSMember-478212000JPY
Total transactions with owners IFRSCurrentYTDDuration_RetainedEarningsIFRSMember936989000JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-936989000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-500594000JPY
Total transactions with owners IFRSCurrentYTDDuration-500594000JPY
Equity IFRSCurrentQuarterInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSCurrentQuarterInstant_CapitalSurplusIFRSMember4502054000JPY
Equity IFRSCurrentQuarterInstant_TreasurySharesIFRSMember-1085546000JPY
Equity IFRSCurrentQuarterInstant_RetainedEarningsIFRSMember28326759000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember1761359000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember37461364000JPY
Equity IFRSCurrentQuarterInstant37461364000JPY
Profit loss before tax IFRSPrior1YTDDuration-368500000JPY
Profit loss before tax IFRSCurrentYTDDuration4661920000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration1375987000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration1828986000JPY
Interest and dividend income ope cf IFRSPrior1YTDDuration-1238000JPY
Interest and dividend income ope cf IFRSCurrentYTDDuration-6021000JPY
Interest expenses ope cf IFRSPrior1YTDDuration129168000JPY
Interest expenses ope cf IFRSCurrentYTDDuration173374000JPY
Foreign exchange loss gain ope cf IFRSPrior1YTDDuration-262984000JPY
Foreign exchange loss gain ope cf IFRSCurrentYTDDuration-304372000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration132986000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration160460000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration-989246000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration5765800000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-364419000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass